You are here
Photos from the National Center for Advancing Translational Sciences (NCATS)
2011
-
Cancer-fighting Strategy
A research team, supported in part by a Penn State University Clinical and Translational Science Institute pilot grant award and research funding from the National Cancer Institute, has developed a promising cancer-fighting strategy for "reactivating" genes that cause cancer tumors to shrink and die. The discovery may aid in the development of an innovative anti-cancer drug that effectively targets unhealthy, cancerous tissue without damaging healthy, non-cancerous tissue and vital organs.
-
Cystic Fibrosis Drug
Patients with a rare type of the deadly lung disorder cystic fibrosis may be able to breathe easier thanks to a new drug that targets the defective protein causing the disease. Researchers from 13 universities and hospitals, including 10 CTSA institutions, partnered with the Cystic Fibrosis Foundation and the drug manufacturer Vertex Pharmaceuticals to conduct clinical trials and obtain FDA approval for the drug Kalydeco as a new treatment.
-
Lung-on-a-Chip
Combining microfabrication techniques with modern tissue engineering, the lung-on-a-chip, designed by the Wyss Institute at Harvard University, offers a new in vitro approach to drug screening by mimicking the complicated mechanical and biochemical behaviors of a human lung. The lung-on-a-chip work was supported by NIH Common Fund and FDA. (The Human-on-a-Chip work at the Wyss Institute is funded by DARPA.)
-
NCATS Laboratory
A technician in an NCATS chemistry laboratory advancing a chemical probe through analog synthesis.
-
NCATS Pharmaceutical Collection
The NCATS Pharmaceutical Collection, also known as the NIH Chemical Genomics Center Pharmaceutical Collection, is a comprehensive, publicly accessible collection of approved and investigational molecular entities for high-throughput screening that provides a valuable resource for both validating new models of disease and better understanding the molecular basis of disease pathology and intervention. NCATS provides access to its set of approved drugs and bioactives through the Therapeutics for Rare and Neglected Diseases program and as part of the compound collection for the Tox21 Initiative, a collaborative effort for toxicity screening among several government agencies including the U.S. Environmental Protection Agency, National Toxicology Program, and U.S. Food and Drug Administration.
2010
-
Sean Mackey, M.D., Ph.D.
Sean Mackey, M.D., Ph.D., of Stanford University School of Medicine and the Stanford Systems Neuroscience and Pain Lab, delivered the 2011 Stephen E. Straus Lecture in the Science of Complementary and Alternative Medicine.
2008
-
Center for Interventional Oncology
Precision is the goal of a new collaboration involving the Clinical Center, the National Cancer Institute, and the National Heart, Lung, and Blood Institute. The Center for Interventional Oncology will pull on the strengths of each to investigate how imaging technology can diagnose and treat localized cancers in ways that are precisely targeted and minimally or non-invasive. Chief of the new Center for Interventional Oncology, Dr. Bradford Wood, demonstrates image-guided tumor ablation in a CC Radiology and Imaging Sciences suite.
